Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final up...
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
About this item
Full title
Author / Creator
for the ERIVANCE BCC Investigators , ERIVANCE BCC Investigators , Sekulic, Aleksandar , Migden, Michael R. , Basset-Seguin, Nicole , Garbe, Claus , Gesierich, Anja , Lao, Christopher D. , Miller, Chris , Mortier, Laurent , Murrell, Dedee F. , Hamid, Omid , Quevedo, Jorge F. , Hou, Jeannie , McKenna, Edward , Dimier, Natalie , Williams, Sarah , Schadendorf, Dirk and Hauschild, Axel
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
In the primary analysis of the ERIVANCE BCC trial, vismodegib, the first US Food and Drug Administration-approved Hedgehog pathway inhibitor, showed objective response rates (ORRs) by independent review facility (IRF) of 30% and 43% in metastatic basal cell carcinoma (mBCC) and locally advanced BCC (laBCC), respectively. ORRs by investigator review...
Alternative Titles
Full title
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
Authors, Artists and Contributors
Author / Creator
ERIVANCE BCC Investigators
Sekulic, Aleksandar
Migden, Michael R.
Basset-Seguin, Nicole
Garbe, Claus
Gesierich, Anja
Lao, Christopher D.
Miller, Chris
Mortier, Laurent
Murrell, Dedee F.
Hamid, Omid
Quevedo, Jorge F.
Hou, Jeannie
McKenna, Edward
Dimier, Natalie
Williams, Sarah
Schadendorf, Dirk
Hauschild, Axel
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_369c8eef082e487e8b1ee700e6160944
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_369c8eef082e487e8b1ee700e6160944
Other Identifiers
ISSN
1471-2407
E-ISSN
1471-2407
DOI
10.1186/s12885-017-3286-5
